Quotient Therapeutics secures $50 million for somatic genomics research
Quotient Therapeutics, a company based in Cambridge, MA and Cambridge, UK, has secured $50 million in initial funding to further its somatic genomics research. The funding round was led by Flagship Pioneering and will be used to advance the development of Quotient's Somatic Genomics platform. The company, led by CEO Geoffrey von Maltzahn, Ph.D., aims to study the genetic variation and evolution of cells in the human body to understand the links between genes and disease. By utilizing their platform, Quotient hopes to discover groundbreaking medicines that can cure, prevent, or reverse diseases.
The Somatic Genomics platform developed by Quotient Therapeutics was created through a collaboration between Flagship scientists, geneticists at the Wellcome Sanger Institute, and the University of Texas Southwestern.
This platform allows for the study of natural selection at the cellular level through various steps, including phenotyping, isolation, genotyping, and computation. Through this process, Quotient is able to identify genes, proteins, and pathways that have been naturally selected and can potentially be targeted for the development of transformative therapies. The company aims to develop first-in-class drugs across multiple therapeutic areas, such as immune disease, cardiometabolic disease, infectious disease, oncology, neurodegenerative disease, rare disease, and aging.
Aside from Geoffrey von Maltzahn, the co-founders of Quotient Therapeutics include Jacob Rubens, Ph.D., President, and Noubar Afeyan, Strategic Oversight Board Chairman. The company also collaborates with Professor Sir Mike Stratton, MD, PhD, Inigo Martincorena, PhD, and Peter Campbell, PhD, from the Wellcome Sanger Institute, as well as Hao Zhu, MD, from the University of Texas Southwestern. Quotient is also supported by a team consisting of Scott Hayton, Ph.D., Acting Chief Operating Officer, Caroline Fox, M.D., MPH, Senior Vice President, Head of Genetics and Target Discovery, and Simon Brunner, Ph.D., Co-Founder and Head of Platform. With research facilities in both Cambridge, MA and Cambridge, UK, Quotient is well-positioned to advance their innovative research and development efforts.
They've invested in Quotient Therapeutics
Get to know these Biotech investors
Click here for a full list of 6,481+ startup investors in the UK